Immunovaccine Prices Prospectus Offering
HALIFAX, NOVA SCOTIA–(Marketwire – Sept. 3, 2010) –
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
Immunovaccine Inc. (“Immunovaccine” or the “Company”) (TSX VENTURE:IMV) voiced which it has concluded with a associate of agents led by Paradigm Capital Inc., and together with Dundee Securities Corporation (collectively, the “Agents”) on the pricing of the open charity (the “Offering”) of equity units (the “Units”) of the Company, which was formerly voiced by the rough short form handbill antiquated Aug 11, 2010.
Each Unit will include of one usual share of Immunovaccine (each, a “Common Share”) and one-half of one usual share squeeze aver (each total usual share squeeze warrant, a “Warrant”). Under the conditions of the group agreement, the Agents will offer, on a most appropriate efforts basis, Units at a cost of $1 per Unit. Each Warrant will accede to the hilt to take one one more Common Share on remuneration of the practice cost of $1.30 for a duration of 36 months following the shutting of the Offering.
The Company will additionally accede to the Agents an choice (the “Agents’ Option”) to squeeze one more Units in an volume up to 15% of the series of Units sole pursuant to the Offering, exercisable in total or in partial at any time up to thirty days following the shutting of the Offering. The Company anticipates filing a last short form handbill on or about Sep 8, 2010 and the Offering is approaching to tighten on or about Sep 16, 2010. Closing is theme to sure conditions including, but not singular to, the taking of all compulsory approvals together with the capitulation of the germane bonds regulatory authorities and the TSX Venture Exchange.
The Company proposes to make use of the net deduction to rise vaccine product possibilities for tellurian illness regulating the DepoVax™ vaccine height and for ubiquitous corporate purposes. A duplicate of the rough handbill relating to the Offering might be performed from the System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedar.com or from Paradigm Capital Inc. at 95 Wellington Street West, Suite 2101, Toronto, Ontario M5J 2N7 or by job (416) 361-9892.
This press recover is not an suggest to sell or the questionnaire of an suggest to buy the bonds in any office in which such offer, questionnaire or sale would be wrong before to gift or registration underneath the bonds laws of such jurisdiction. The bonds being offering have not been, nor will they be, purebred underneath the United States Securities Act of 1933, as amended, and such bonds might not be offering or sole inside of the United States or to, or for the comment or good of, U.S. persons absent registration or an germane grant from U.S. registration requirements.
Immunovaccine Inc. (TSX VENTURE:IMV) is a clinical theatre vaccine growth association focused on the commercialization of the law DepoVax™ vaccine smoothness record and product candidates. The association continues to make firm the vaccine tube by chartering and vital partnerships to rise healing cancer and spreading mildew vaccines. www.imvaccine.com
This press recover contains forward-looking report underneath germane bonds law. All report which addresses activities or developments which we design to start in the destiny is forward-looking information. Forward-looking statements have been formed on the estimates and opinions of government on the date the statements have been made. However, they should not be regarded as a illustration which any of the skeleton will be achieved. Actual formula might talk about materially from those set onward in this press recover due to risks inspiring the Company, together with entrance to capital, the successful execution of clinical trials and taking of all regulatory approvals. Immunovaccine Inc. assumes no shortcoming to refurbish forward-looking statements in this press recover solely as compulsory by law.
Neither TSX Venture Exchange nor the Regulation Services Provider (as which tenure is tangible in the policies of the TSX Venture Exchange) accepts shortcoming for the endowment or correctness of this release.
